实时全球研报
Managed Medicaid: Read Across from ELV and UNH‘s Medicaid Commentary
研报英文原文证据摘录
Managed Medicaid: Read Across from ELV and UNH‘s Medicaid Commentary
J P M O R G A N North America Equity Research
17 July 2026
Managed Medicaid
Read Across from ELV and UNH’s Medicaid
Commentary
We wanted to follow up on UNH’s commentary on Thursday and ELV’s Managed Care and Facilities
ACcommentary on Wednesday as they relate to Managed Medicaid MCOs. We'd John Stansel, CFA
frame the commentary as defending/reaffirming existing Medicaid guidance, but (1-212) 622-0083
with our interpretation of ELV’s commentary suggesting that utilization was john.stansel@jpmorgan.com
running higher (offset by rate favorability). The commentary is not colossally Lisa C. Gill
negative on its own, but it doesn't make the case for Medicaid outperformance (1-212) 622-6466
versus guidance (which we believe both MOH/CNC saw in 1Q), and while we lisa.c.gill@jpmorgan.com
think current consensus expectations for both CNC and MOH don't assume further Benjamin Rossi
outperformance in MLR for 2Q, we think CNC/MOH’s multiple expansion post- (1-212) 622-9603
benjamin.rossi@jpmorgan.com
1Q (CNC ~2-turn expansion on 2027e P/E to 14x since April and MOH ~4-turn
Cole Harrisexpansion to 24x) suggests investors expect that 2Q will see MLR outperformance
(1-212) 622-9068
with increases to adj. EPS guidance (although we think much of this rests on the cole.harris@jpmorgan.com
ACA Exchanges for CNC). The commentary around potential Medicaid market J.P. Morgan Securities LLC
exits by ELV over the next 12-18 months strikes us as a short-term opportunity for
market share in Medicaid, with some longer-term caveats. Putting it all together,
while we think the Bloomberg consensus MLRs are reasonable for 2Q, we believe
investor expectations may be higher, and given the more neutral tone on Medicaid
本摘录由系统从所标注的 PDF 证据页直接提取并保留英文原文,不做批量翻译;登录后在阅读器切换中文时才按需翻译。
打开研报阅读器